Tag Archives: GU oncology
Dr. Petros Grivas: The Journey from Greece to the US, and the Difficult Question of When to Move
Dr. Monty Pal: From an Early Commitment to Medicine Down the Path to ASCO & GU Oncology Leadership
TIP or BEP for Intermediate or Poor Risk Testicular Cancer?: Highlights in GU Oncology from ASCO 2018 (BMIC-061)
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for intermediate/poor risk germ cell tumors, with discussion of outcomes in patients with a p53 mutation. (3:39)
Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, assessing the benefit of adjuvant docetaxel for patients after radiation for patients with high or intermediate risk localized prostate cancer. (1:34)
What is Positive Predictive Value of PET PSMA in Biochemical Recurrence of Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-059)
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate cancer, as presented by Wolfgang Fendler & colleagues at ASCO 2018. (2:46)
New Data & Context for a PARP Inhibitor/Abiraterone Combination in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-058)
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unselected metastatic prostate cancer, along with providing a context of results from similar prior research. (3:02)
Is PROSTVAC the Vaccine Therapy We’ve Been Waiting for in Advanced Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-057)
Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials that fail in phase III despite looking extremely favorable in phase II studies. (2:02)
Is More Better with Radium-223 for Metastatic Prostate Cancer? Highlights in GU Oncology from ASCO 2018 (BMIC-056)
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration of radium-223 (Xofigo) compared to standard dosing for 6 months with this agent in patients with metastatic prostate cancer. (1:07)
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients. (2:17)